Image pharmaphorum Editor R&D How Design of Experiments enriches life sciences’ findings Design of Experiments (DOE) is a methodology misunderstood by many, understood by some, and actively used by even fewer than that. Oncology Sponsored How can digital and AI optimise the delivery of patient supp... How can digital and AI optimise the delivery of patient support programs in cancer? Digital 2023 predictions and challenges in the healthcare business With a new year comes an opportunity for professionals in the healthcare industry to evaluate goals and initiatives for 2023. Patients Nine for 2023, part two: healthcare’s hard problem, the prog... The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, Load more results
R&D How Design of Experiments enriches life sciences’ findings Design of Experiments (DOE) is a methodology misunderstood by many, understood by some, and actively used by even fewer than that.
Oncology Sponsored How can digital and AI optimise the delivery of patient supp... How can digital and AI optimise the delivery of patient support programs in cancer?
Digital 2023 predictions and challenges in the healthcare business With a new year comes an opportunity for professionals in the healthcare industry to evaluate goals and initiatives for 2023.
Patients Nine for 2023, part two: healthcare’s hard problem, the prog... The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year,
Digital Axtria Ignite 2025: Madhavi Ramakrishna on leadership, cultu... GSK's Madhavi Ramakrishna was the recipient of one of the annual Axtria Ignite Leadership Awards presented at the invite-only summit.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
